Altimmune announces successful completion of end-of-phase 2 meeting with fda for pemvidutide in the treatment of obesity

Company and agency aligned on key efficacy and safety measures to be studied in phase 3 program pivotal phase 3 trials designed to leverage the differentiated attributes of pemvidutide and potential benefits of balanced glp-1/glucagon dual agonism gaithersburg, md., nov. 07, 2024 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced the successful completion of its end-of-phase 2 meeting with the u.s. food and drug administration (fda) and agreement on the design of a phase 3 registrational program for its product candidate, pemvidutide, in the treatment of obesity.
ALT Ratings Summary
ALT Quant Ranking